


Data Sheet

Product Name:	Duvelisib
Cat. No.:	HY-17044
CAS No.:	1201438-56-3
Molecular Formula:	C ₂₂ H ₁₇ ClN ₆ O
Molecular Weight:	416.86
Target:	PI3K
Pathway:	PI3K/Akt/mTOR
Solubility:	DMSO: ≥ 41 mg/mL



BIOLOGICAL ACTIVITY:

Duvelisib is a novel and selective **PI3K δ/γ** inhibitor with **K_i** and **IC₅₀** of 23 pM/243 pM and 1 nM/50 nM, highly selective for PI3K δ/γ than other protein kinases.

IC₅₀ & Target: IC₅₀: 1 nM (PI3K δ), 50 nM (PI3K γ)

In Vitro: PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells^[1].

References:

[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. *Oncotarget*. 2016 Jun 28;7(26):39784–39795.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA